QART (Quantitative Assisted Reproductive Technologies) Medical, a clinical-stage MedTech company, addressing the global infertility epidemic. The Company develops a breakthrough solution for highly informative characterization and selection of sperm cells for in-vitro fertilization (IVF), aiming to create a new and better gold standard in the ART market. The QART system aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by:
* Quantitatively characterizing the morphology and contents of individual sperm cells with 3D topographic imaging
* Providing quantitative DNA integrity information, on a cell-by-cell basis
* Automatically sorting a semen sample according to objective consensus criteria.
|2019||Mar 2019 08:30 PM||10717|
|2020||Nov 2020 08:33 PM||10717|
|2019||Nov 2019 08:36 PM||10717|
The QART solution is based upon a first-in-class, stain-free, real-time 3D imaging system that provides a quantitative topographic map of the sperm morphology and its inner contents.
The system is a compact, stand-alone bench-top clinical workstation.
It is based upon a built-in quantitative phase interferometric microscopy (IPM) imaging microscopy platform, and has a microfluidics sorting stage, all controlled via a simple personal computer.
Per ICSI cycle, a disposable cartridge, containing the semen specimen, is inserted into the workstation.